infection protection: Live & Latest News Updates : Vimarsana.com

🇩🇪 Germans Vs The Menace

https://vimeo.com/581792932

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

– VOWSTTM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI ...

Seres Therapeutics to Present at Goldman Sachs Global Healthcare Conference

Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced that Seres Therapeutics management, will participate in a question and answer format discussion at the Goldman... | June 9, 2023

Cholera Response in Malawi: The Role of an IPC Specialist During a Level 3 Emergency - Malawi

News and Press Release in English on Malawi about Health and Epidemic; published on 29 May 2023 by WHO

Seres Therapeutics to Present at Jefferies Healthcare Conference

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events – – Reduction in incidences of microbiome pathogen... | May 9, 2023

Seres Therapeutics (MCRB) Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination

Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023

- Company to report initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1 - ... | May 5, 2023

Seres Therapeutics Announces $250 Million Debt Financing with Oaktree